DrugPatentWatch Database Preview
« Back to Dashboard
Betamethasone dipropionateis the generic ingredient in thirteen branded drugs marketed by Anda Repository, Fougera Pharms, Glenmark Generics, Perrigo Israel, Taro, Schering, Merck Sharp Dohme, Savage Labs, Actavis Mid Atlantic, Cosette, Perrigo New York, Pharmaderm, Teva, Zydus Pharms, Akorn, Teligent, Alpharma Us Pharms, Fougera Pharms Inc, Invatech, Lupin Ltd, Cadila, Taro Pharms, Primus Pharms, Leo Pharma As, MC2, Perrigo Uk Finco, Tolmar, and Glenmark Pharms, and is included in seventy-three NDAs. There are sixteen patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.
Betamethasone dipropionate has seven patent family members in five countries.
There are sixty-six drug master file entries for betamethasone dipropionate. Twenty-five suppliers are listed for this compound.
Summary for betamethasone dipropionate
|Drug Master File Entries:||66|
|Finished Product Suppliers / Packagers:||25|
|Raw Ingredient (Bulk) Api Vendors:||45|
|Formulation / Manufacturing:||see details|
|Drug Prices:||Drug price trends for betamethasone dipropionate|
|Drug Sales Revenues:||Drug sales revenues for betamethasone dipropionate|
|Patent Litigation and PTAB cases:||See patent lawsuits and PTAB cases for betamethasone dipropionate|
|What excipients (inactive ingredients) are in betamethasone dipropionate?||betamethasone dipropionate excipients list|
|DailyMed Link:||betamethasone dipropionate at DailyMed|
Recent Clinical Trials for betamethasone dipropionate
Identify potential brand extensions & 505(b)(2) entrants
|University of Alabama at Birmingham||Phase 4|
|Eli Lilly and Company||Phase 4|